Q2 2026 Compugen Ltd Earnings Call Transcript
Key Points
- Compugen Ltd (CGEN) is advancing its wholly-owned COM701 program with the MyOvarian trial on track for an interim analysis by Q1 2027, targeting a high unmet need in platinum-sensitive ovarian cancer.
- AstraZeneca's continued investment in rilvegostomig, including a new Phase III trial in urothelial carcinoma, underscores confidence in the asset and its potential to generate milestones and royalties for Compugen Ltd (CGEN).
- New data from AstraZeneca's GEMINI hepatobiliary study showed a median overall survival of 16.8 months in first-line biliary tract cancer, exceeding historical benchmarks of less than 13 months.
- Compugen Ltd (CGEN) maintains a solid cash position of $125.3 million, with a runway expected to fund operations into 2029, supporting ongoing clinical and pipeline activities.
- The company's AI-driven platform, Unigen, continues to deliver innovative targets, with GS0321 (licensed to Gilead) progressing as planned in Phase I dose escalation, offering additional upside through milestones and royalties.
- Compugen Ltd (CGEN) revised its estimated median PFS for the placebo control arm in the MyOvarian trial down to approximately four months, reflecting a more heavily pretreated patient population and potentially higher hurdle for demonstrating COM701's benefit.
- The MyOvarian trial is not powered to show a statistical difference, and the interim analysis relies on a relatively small sample size (40 patients on COM701 vs. 20 on placebo), which may limit the strength of conclusions.
- No regulatory interactions with the FDA have occurred for the MyOvarian trial, and the path to approval remains uncertain, with the company only noting alignment with Project Front Runner guidelines.
- Phase III readouts for rilvegostomig are not expected until after 2027, meaning potential milestones and royalties from AstraZeneca are likely several years away.
- The company's net loss of $7 million in Q2 2026, while slightly improved year-over-year, reflects ongoing R&D and G&A expenses with no near-term product revenue, relying on partnerships for cash inflows.
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's second quarter 2026 results conference call. At this time, all participants are in listen-only mode. An audio webcast of this call is available in the Investors section of Compugen's website at www.cgen.com. As a reminder, today's call is being recorded. I will now hand the call over to Lindsay Trickett, Head of Investor Relations and Corporate Communications, to begin. Lindsay, please go ahead.
Thank you, operator. Good morning and good afternoon, everyone, and welcome to Compugen's Second Quarter 2026 Financial Results Conference Call. With us today are Dr. Eran Ophir, President and Chief Executive Officer, and David Silberman, Chief Financial Officer. Dr. Michelle Mahler, Chief Medical Officer, will join us for the Q&A portion of the call.
Before we begin, I'd like to remind you that during this call, the company may make projections or forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
